Keybanc Maintains Overweight on Absci, Raises Price Target to $20
10/16/2026
Impact: 70
Healthcare
Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on Absci (NASDAQ: ABSI) and raised the price target from $16 to $20. This adjustment reflects a positive outlook for the company in the market.
AI summary, not financial advice
Share: